ASLAN Pharmaceuticals

You are now leaving our web site.

The Website may contain links to or from other websites, over which ASLAN has no control. These linked sites are for your convenience only and you access them at your own risk.

ASLAN is not responsible for the content of the linked sites. ASLAN does not in any way endorse the linked sites.

I understand

Our Pipeline

Our portfolio is led by ASLAN004, a novel, first-in-class antibody targeting the IL-13 receptor that has the potential to be best-in-disease for atopic dermatitis.

Programs
Target
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Anticipated Milestones
Eblasakimab(ASLAN004)

IL-13Rα1
Atopic dermatitis (AD)

Phase 1b biomarker and PRO data in 2H 2022
Phase 2b topline data in 1H 2023

Type 2-driven disease
Farudodstat(ASLAN003)

DHODH
Inflammatory bowel disease

Initiate Phase 2 in 1H 2022

Autoimmune skin disease


Eblasakimab

Phase 2

Novel, first-in-class antibody targeting IL-13R with the potential to be best-in-disease for atopic dermatitis.

Read more about Eblasakimab

Farudodstat

Phase 2

Potential to be the most potent oral DHODH inhibitor currently in development for autoimmune disease

Read more about Farudodstat

Therapeutic Areas

We focus on atopic dermatitis, other immunology indications and autoimmune disease.

Atopic dermatitis

Atopic dermatitis

Atopic dermatitis is the most common dermatological disease, affecting over 200 million patients worldwide. Up to one-third of adult atopic dermatitis patients are considered moderate-to-severe, for which currently available therapeutics are limited and management is challenging in the majority of cases.

ASLAN004 is a fully human monoclonal antibody that targets the IL-13 receptor α1 subunit, or IL-13Rα1, with potential to be a first-in-class therapy for atopic dermatitis. ASLAN004 is currently undergoing a phase 1 study for the treatment of atopic dermatitis. The SAD portion of the study was completed in the second quarter of 2019. The MAD portion of the study is ongoing. Positive interim data was announced in March 2021, and top line data is expected in mid-2021.